Background: Poly(ADP-ribose)polymerase-1 (PARP-1) is a highly promising novel target in breast cancer. However, the expression of PARP-1 protein in breast cancer and its associations with outcome are yet poorly characterized.
introduction Poly(ADP-ribose)polymerase-1 (PARP-1) belong to a superfamily of 17 structurally related members that catalyzes the cleavage of NAD + molecules resulting in the incorporation of ADP-ribose molecules to acceptor proteins [1] . Poly(ADPribosyl)ation and PARPs proteins have been involved in various cellular processes including cell survival and death, transcription, DNA repair, telomere integrity and cell division [2, 3] . The nuclear protein PARP-1 is the most abundant member of the PARP superfamily and DNA damage-dependent PARP activity is mainly carried out by PARP-1 [4] .
There is increasing interest in developing PARP inhibitors for cancer therapy [5] [6] [7] . In breast cancer models, PARP inhibition sensitized p53-deficient cells to doxorubicin-induced apoptosis [8] and selectively killed cells with hereditary inactivating mutations in BRCA1 and BRCA2, which encode proteins critical for DNA repair by homologous recombination [9, 10] . PARP inhibitors might be also active in nonhereditary breast cancer cells lacking mutations in BRCA1 or BRCA2 [7, 11, 12] . Phase I and II trials with olaparib, an orally active PARP inhibitor, have shown antitumor activity in hereditary breast and ovarian cancers harboring mutations in BRCA1 or BRCA2 [13] . Another drug initially thought to inhibit PARP, iniparib, was tested in metastatic breast cancer with a triple-negative [human epidermal growth receptor 2 (HER2)-negative, estrogen receptor (ER)-negative and progesterone receptor (PR)-negative] phenotype, which shares several features with BRCA1/2-mutated tumors [14] . In a phase II randomized study, iniparib in combination with gemcitabine/carboplatin chemotherapy yielded promising results [15] . However, a phase III study of iniparib in combination with cytotoxic therapy failed to meet significance for co-primary end points of overall and progression-free survival [16] . This phase III trial involved 519 women with metastatic triple-negative breast cancer. All patients received gemcitabine and carboplatin and were randomized to iniparib or placebo. The iniparib arm had a median progression-free survival of 5.1 months compared with 4.1 months in the placebo group. Median overall survival (OS) was 11.8 months with iniparib and 11.1 months in the placebo arm (P = 0.28). An exploratory analysis of the primary end points showed that patients receiving first-line metastatic therapy had similar OS and progression-free survival. In contrast, patients in second-and third-line therapy had a median progression-free survival of 4.2 months with iniparib and 2.5 months with placebo [16] . Other phase II trials with PARP inhibitors are under way [17] .
These recent conflicting results illustrate that the development of PARP inhibitors for breast cancer therapy is very challenging and that there is an urgent need to understand much better the expression and role of the drug target. At present, the expression of PARP proteins in breast cancer and its main clinical associations are insufficiently characterized [18] [19] [20] [21] . In this context, we developed a PARP-1 immunohistochemical assay. We then assayed PARP-1 expression in a series of breast cancer specimens (N = 330) from patients with clinical follow-up.
materials and methods

patients and specimens
Surgical resection specimens from primary breast tumors and mammoplasties obtained from Parc de Salut Mar Biobank (MARBiobanc, Barcelona, Spain), Fundació n Jiménez Díaz Biobank (Madrid, Spain) and Valencia Clinic Hospital Biobank (Valencia, Spain). Tumor specimens from formalin-fixed paraffin-embedded (FFPE) blocks were retrospectively selected from consecutive breast cancer patients diagnosed between 1998 and 2000, which had the following criteria: infiltrating carcinomas, operable, no neoadjuvant therapy, enough available tissue and clinical follow-up.
TNM (tumor-node-metastasis) staging was classified using the American Joint Committee on Cancer (AJCC) staging system. Histological grade was defined according Scarff-Bloom-Richardson modified by Elston [22] . ER and PR were determined by immunohistochemistry (IHC) (SP1 and PgR636 clones, respectively; Dako, Carpinteria, CA) establishing positivity criteria in ‡1% of nuclear tumor staining [23] . HER2 amplification was assayed by FISH (Pathvysion; Abbott Laboratories, Abbott Park, IL) [24] . Ki-67 was studied by IHC (MIB1 clone; Dako) [25] . Patients referred to genetic counseling were studied for BRCA1 and BRCA2 gene status by direct sequencing. The study was approved by the Ethics Committees of the three hospitals.
Three hundred and thirty infiltrating carcinomas were collected. Tissue microarrays (TMA) were constructed as reported [26] . Fresh frozen tumor samples were also included (N = 18). Complete sections of infiltrating carcinoma (N = 153), adjacent histologically normal tissue (N = 25), ductal hyperplasia lesions (N = 75) and ductal carcinoma in situ (DCIS) (N = 102) from the same specimens were assayed. A cohort of 42 patients with previously known BRCA status was also studied for PARP-1. Normal breast tissue specimens (N = 50) obtained from noncancerous mammoplasties were included.
PARP-1 immunostaining
Immunostaining was carried out using 3-lm sections. Heat antigen retrieval was carried out in pH 9 EDTA-based buffered solution in a Dako Link platform. Endogenous peroxidase was quenched. A mouse monoclonal anti-PARP-1 antibody (Clone A6.4.12) [27] was used for 30 min at room temperature, 1 : 300 dilution, followed by incubation with a polymer coupled with peroxidase (Flex+; Dako). Sections were then visualized with 3,3#-diaminobenzidine (DAB) and counterstained with Hematoxylin.
PARP-1 antibody sensitivity (1 : 300) had been calculated in a range of crescent dilutions of primary antibody. Specificity was determined using wild-type and PARP-1 gene knockout mouse embryonic fibroblasts (MEF) and parental and stably PARP-1 small interfering RNA (siRNA) transduced BT474, MCF7 and MDA-MB231 human breast cancer cells. Specificity was also shown in kidney and liver tissue specimens from wild-type and PARP-1 knockout mice. Formalin-fixed cell pellets were processed as described for IHC and results confirmed by western blot. A set of paired fresh frozen and FFPE samples was processed by western blot and IHC. Sections incubated with normal mouse immunoglobulin G2 were used as controls.
PARP-1 immunostaining was scored by a computerized measurement using a DM2000 Leica microscope equipped with the Nuance FX Multispectral Imaging System (CRI Inc., Woburn, MA) [28] . A library of pure DAB and Hematoxylin dye colors was created and used to unmix colors. A stack of images at different wavelengths was then acquired, followed by spectral imaging of three representative fields. After image deconvolution, the spectral data was flat fielded to compensate for unevenness in illumination and background was filtered. Positive signals were converted to optical density units by taking the negative log of the ratio of the sample divided by the reference. A computer-aided analysis yielded quantitative data of PARP-1 from the average intensity of regions of interest and a pseudo-color image that highlights positive signals was set. Only the nuclei of epithelial cells (normal and malignant), but not stromal cells, were automatically detected by setting distinct size threshold and confirmed by a pathologist. Mean value of the signal intensity of each case was calculated. The output of the measurement produced a continuous data ranging from 29 to 133 094.
statistics
Statistical analysis was carried out with SPSS v13.0 (SPSS-IBM, Armonk, NY). We hypothesized that the group of women with tumors nonoverexpressing PARP-1 would have an 80% 5-year OS and the group overexpressing PARP-1 a 65% 5-year OS. The minimal sample needed to detect this difference, with a power of 0.90 and two-sided error a of 0.05, was 241 cases. To correlate PARP-1 expression and clinicopathological variables, we used the v 2 test (Fisher's exact test). OS was defined as the time from the date of surgery to the date of death from any cause or last follow-up. Diseasefree survival (DFS) was considered from the date of surgery to the date of any primary, regional or distant recurrence, as well as the appearance of a secondary tumor or DCIS. Univariate analysis was based on the KaplanMeier OS and DFS curves using the log-rank test; all predictors with P-values <0.1 were used in multivariate analysis using the Cox proportional hazards model [18] . All the statistical tests were conducted at the two-sided 0.05 level.
Receiver operating curve (ROC) was used to determine the optimal cutoff point based on relapse end point for PARP-1 expression, [29] . As shown in 'Results', the cut-off was set for an optical density of 39 970. Specimens with values above this cut-off point were considered as PARP-1 overexpressors and specimens with values below non-overexpressors. This work was carried out in accordance with Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) guideline [30] .
results
PARP-1 staining assay validation
Specificity of PARP-1 IHC assay was tested in FFPE pellets from wild-type and PARP-1 gene knockout MEFs, parental and PARP-1 siRNA knocked down human breast cancer cells and kidney and liver tissues form wild-type and PARP-1 knockout mice. All assays revealed a nuclear staining in the wild-type and parental samples (Supplemental Figure S1A , available at Annals of Oncology online), confirmed as a single band at 113 kD detected by western blot (Supplemental Figure S1B , available at Annals of Oncology online). Eighteen paired fresh frozen and FFPE samples were also processed by western blot (Supplemental Figure S1C , available at Annals of Oncology online) and IHC showing concordant results (P < 0.001, R 2 = 0.965). IHC results in 153 infiltrating carcinomas assayed in TMA cores or their corresponding complete tissue sections were comparable (P = 0.002, R 2 = 0.757).
PARP-1 staining in normal and pathological breast
Breast ductal and lobular epithelial cells exhibited diffuse and weak PARP-1 staining in the nuclei. In stromal cells and lymphocytes, nuclear PARP-1 staining was commonly detected. In usual ductal hyperplasia, the expression was similar to normal breast epithelium. All cases (but one) of ductal hyperplasia had no PARP-1 overexpression. In contrast, in 33.3% of DCIS, PARP-1 was overexpressed, more frequently in high-grade DCIS and comedocarcinomas. PARP-1 staining was exclusively nuclear and diffusely present. In specimens with infiltrating carcinoma associated to DCIS, the in situ component had on average a score of PARP-1 expression 50% higher than the infiltrating counterpart, but the difference was not significant (P = 0.081). In the entire series (N = 330), PARP-1 was overexpressed in 31.2% of infiltrating carcinomas ( Figure 1 ).
PARP-1 staining and clinicopathological features in breast cancer patients
Clinicopathological characteristics and PARP-1 overexpression are shown in overexpression of PARP-1 and patient outcome
As mentioned in 'Materials and Methods', receiver operating curve (ROC) was used to determine the optimal cut-off point for PARP-1 expression. The area under the curve for PARP-1 was 0.809 (95% CI 0.743-0.875). Examination of the coordinates of the curve indicates that an optimal cut-off point for PARP-1 was 39 970. At this value, the sensitivity of the test was 79.7%, with a specificity of 80.2% (Figure 2A ). DFS and OS analysis showed a higher risk of relapse or death, respectively, in patients with PARP-1 overexpression (Figure 2B and C; log-rank test, P < 0.001, Table 2 and Supplemental Table  S1 , available at Annals of Oncology online). These associations were also observed in analysis carried out in the subset of patients treated with chemotherapy (CMF or anthracyclinebased, n = 248; P < 0.001 for both DFS and OS), in patients treated with anthracycline-based adjuvant chemotherapy (N = 176; P < 0.001 for both DFS and OS) or in patients treated with hormonal therapy with or without chemotherapy (N = 237; P < 0.001 for DFS and P = 0.008 for OS). The hazard ratio (HR) for relapse in patients with PARP-1 overexpressing tumors was 8.87 (95% CI; 5.05-15.59). Kaplan-Meier curves for relapse and log-rank test comparisons also showed that primary tumor size (P = 0.007), axillary lymph node involvement (P < 0.001), hormone receptor (ER-and/or PR-positive versus both negative) status (P = 0.033) and HER2 (P = 0.023) were associated with the risk of relapse (Supplemental Table S1 , available at Annals of Oncology online). The HR for death in patients with PARP-1-overexpressing tumors was 7.24 (95% CI; 3.56-14.75). Kaplan-Meier survival curves for OS and logrank test comparisons also showed that primary tumor size (P = 0.015), tumor grade (P = 0.03), lymph node involvement (P < 0.001), hormone receptor status (P = 0.03), triple-negative phenotype (P = 0.039) and adjuvant chemotherapy (P = 0.011) were associated with the risk of death (Table 2) .
A multivariate analysis was carried out including all the baseline clinicopathological factors with P-values <0.1 (Table 2  and Supplemental Table S1 , available at Annals of Oncology online). PARP-1 overexpression retained its adverse prognostic role for relapse (P < 0.001) and death (P < 0.001). The HR for relapse (Supplemental Table S1 , available at Annals of Oncology online) in PARP-1 overexpressing tumors was 10.05 (95% CI; 5.42-18.66) and for death ( Table 2 ) was 1.82 (95% CI; 1.32-2.52). Other independent prognostic factors were for lymph nodes (P = 0.038) for DFS and adjuvant chemotherapy (P < 0.001) for OS.
discussion
In the present study, we report that PARP-1 protein overexpression occurs in about a third of both infiltrating and original articles Annals of Oncology in situ breast carcinomas. In infiltrating carcinomas, PARP-1 overexpression was significantly more frequent in high-grade tumors, ER-and triple-negative tumors. Notably, PARP-1 overexpression was an independent adverse prognostic factor. This finding suggests that PARP-1 may play a role in the clinical behavior of breast cancer.
Among the family members of PARP, we focused on PARP-1 because is the most abundant member and the major player in single-strand repair via the base excision pathway [1] . A few studies have reported PARP-1 mRNA and/or protein expression in human tumors [19, [31] [32] [33] [34] [35] . In breast cancer, a recent meta-analysis carried out in a large public retrospective gene expression dataset (n = 2485), revealed that PARP-1 messenger RNA (mRNA) was overexpressed in over half of the cancers and correlated with basal breast cancers and was associated with a worse prognosis, in terms of metastasis-free survival and OS [18] . However, PARP-1 expression was also found in other subtypes. PARP-1 expression retained its prognostic value in a multivariate analysis in the group of patients who had not received adjuvant chemotherapy. In that study, mRNA PARP-1 expression and gain/amplification at the PARP-1 locus were significantly associated. In another large study on gene expression profile, mean PARP1 expression was significantly higher in infiltrating ductal breast cancer relative to normal breast tissue. PARP-1 gene up-regulation was more common in breast tumors with negative ER, PR or HER2. IHC showed that up-regulation of the PARP1 gene was consistent with increased protein expression in triple-negative breast cancer [20] . Here, we focused on PARP-1 protein expression instead of mRNA for various reasons. First, several factors underlie PARP-1 protein up-regulation, including mRNA overexpression [19, 36] , PARP-1 gene and promoter polymorphisms [37] and posttranscriptional modulation [ [38] [39] [40] [41] . Second, PARP-1 protein expression correlated with activity in peripheral blood mononuclear cells from healthy volunteers and patients with solid tumors [42] . Third, the clinical application of IHC may be easier than for other tests, albeit all may be useful.
We found that PARP-1 protein overexpression occurs at the in situ stage. The up-regulation of PARP-1 at early stages of breast malignant transformation is consistent with findings in other tumors [43] [44] [45] . PARP-1 protein overexpression was significantly associated to high tumor grade, absent ER, triple-negative status and patient outcome. In another study, PARP-1 overexpression was also significantly higher in BRCA1-mutated cancers [21] . Of note, PARP-1 overexpression was also present in a fraction of HER2-positive and hormone receptor-positive breast cancers. A recent study addressing homologous recombination (HR) also showed that HR is commonly defective in triple-negative breast cancer but also in other subtypes [46] . Taken together, our finding of high expression of PARP-1 in all subtypes of breast cancer, also reported by others [18, 20, 46] supports the notion that PARP-1 inhibitors may play a role in triplenegative breast cancer, but also potentially in other breast [47] and HER2 [48] . Our results provide novel evidence on nuclear PARP-1 protein overexpression as a promising prognostic factor for relapse and death. A multivariate analysis indicated that it was an independent prognostic factor for both disease-free (HR 10.05) and OS (HR 1.82). Weaknesses of our study are its retrospective nature and the lack of information on the possible relationship between PARP-1 expression and response to PARP inhibitors. However, we believe that the independent prognostic value of nuclear PARP-1 in a large cohort of breast cancer patients with long-term clinical follow-up raises the need of further assessment of the prognostic role of PARP-1, ideally in archival material from patients enrolled in clinical trials and with long-term followup. This result is in agreement with a prior study discussed above [18] that assessed PARP-1 gene expression. The wide range of expression also supports the importance of assaying PARP-1 in tumor specimens from patients treated with PARP inhibitors to analyze its potential predictive value. Nuclear PARP-1 staining was also a poor prognostic factor in melanoma and ovarian carcinoma [31, 32] . We assayed Ki-67 to analyze whether PARP-1 expression levels correlated with proliferation. However, we did not observe a significant association between both variables. A number of additional mechanisms support a role for PARP-1 in tumor progression, including angiogenesis and growth [49] [50] [51] [52] . PARP-1 has been also related to cancer through NF-jB activation [53] . Another possible explanation is that in some cases, PARP-1 overexpression is due to a defective PARP-1 cleavage, thus resulting in reduced tumor apoptosis [34, 54] . In short, PARP-1 has pleiotropic biological functions through their physical association with, or by the poly(ADP-ribosyl)ation of their partner proteins, that may explain its association with poor outcome.
In closing, we report nuclear PARP-1 overexpression in approximately a third of breast cancers. PARP-1 overexpression was more frequent in triple-negative tumors, but was also present in a proportion of hormone receptor-positive or HER2-amplified breast cancers. The variable expression of PARP-1 justifies further studies addressing its relationship with the clinical efficacy of PARP inhibitors. In addition, PARP-1 overexpression independently predicted for poor DFS and OS in patients with early breast cancer. 
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